What type of study is this?

This is a In Vitro Study study.

December 8, 2025BloodOpen Access

In Vivo correction of the sickle cell disease mutation in hematopoietic stem cells using RNA gene writers

View Full Paper

Ask AI

Bookmark

Authors

RNA gene writers demonstrate effective gene correction in hematopoietic stem cells from SCD models, indicating potential for safer treatments.

Therapeutic editing of HBB achieved 74% efficiency in hematopoietic stem cells, demonstrating robust correction.
Editing led to 98% restoration of adult hemoglobin levels, as confirmed by Liquid Chromatography-Mass Spectrometry.
RNA gene writers were administered using lipid nanoparticles for effective in vivo genome editing in multiple models.
Outcomes imply a scalable and safer approach to treating sickle cell disease and other hematologic disorders.

Schiroli et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

RNA gene writers demonstrate effective gene correction in hematopoietic stem cells from SCD models, indicating potential for safer treatments.

Therapeutic editing of HBB achieved 74% efficiency in hematopoietic stem cells, demonstrating robust correction.
Editing led to 98% restoration of adult hemoglobin levels, as confirmed by Liquid Chromatography-Mass Spectrometry.
RNA gene writers were administered using lipid nanoparticles for effective in vivo genome editing in multiple models.
Outcomes imply a scalable and safer approach to treating sickle cell disease and other hematologic disorders.

Schiroli et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark